In the following discussion, we break NDD programs into nine categories, as the chart above shows ... for prevention and prosecution of domestic violence and reduction of drug trafficking. Nearly a ...
The guidance comes as drug regulatory submissions citing AI have increased exponentially. In an interview with STAT in October, the FDA’s Tala Fakhouri, who co-leads the Center for Drug ...
Of that, approximately 51 percent of total pharmaceutical spending was on specialty drug products, increasing at a faster rate than non-specialty drug spending. In 2021, Delaware’s Department of ...
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim ...
Here’s a glide path for the 119th Congress to target a surge in costly Biden rules with the Congressional Review Act and ...
Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial. The trial will be conducted at CMAX, one of Australia’s leading clinical research centers, ...
The regulatory basis and compliance examples from FDA observations and warning letters are included to support the need for an effective process. The Center for Drug Evaluation and Research’s new ...
The product was distributed nationwide to wholesale and retail outlets. Astellas is notifying its customers via a drug recall notification letter and is arranging for the return of the impacted ...
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice from ...
Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened ...
However, she said a lot of things need to happen first, including the injectable drug receiving regulatory approvals from authorities like the United States Food and Drug Administration and the ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...